The stock of microcap Bionomics Ltd. rose 103% early Thursday, after the company reported positive results from a mid-stage trial of a treatment for post-traumatic stress disorder.
The trial, which was called Attune, involved 212 patients at 34 sites in the U.S. and U.K. who were given either 900 mgs of BNC210 twice daily or a placebo. The patients were aged 18 to 75. The company is hoping the results will enable talks with the U.S. Food and Drug Administration on the registrational path of BNC210 in PTSD, which in an indication with high unmet need, he added.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: